Literature DB >> 27609631

Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection.

Héctor Meijide1, Álvaro Mena2, Iria Rodríguez-Osorio3, Sonia Pértega4, Ángeles Castro-Iglesias3, Guillermo Rodríguez-Martínez5, José Pedreira3, Eva Poveda3.   

Abstract

BACKGROUND: New patterns in epidemiological characteristics of people living with HIV infection (PLWH) and the introduction of Highly Active Antiretroviral Therapy (HAART) have changed the profile of hospital admissions in this population. The aim of this study was to evaluate trends in hospital admissions, re-admissions, and mortality rates in HIV patients and to analyze the role of HCV co-infection.
METHODS: A retrospective cohort study conducted on all hospital admissions of HIV patients between 1993 and 2013. The study time was divided in two periods (1993-2002 and 2003-2013) to be compared by conducting a comparative cross-sectional analysis.
RESULTS: A total of 22,901 patient-years were included in the analysis, with 6917 hospital admissions, corresponding to 1937 subjects (75% male, mean age 36±11 years, 37% HIV/HCV co-infected patients). The median length of hospital stay was 8 days (5-16), and the 30-day hospital re-admission rate was 20.1%. A significant decrease in hospital admissions related with infectious and psychiatric diseases was observed in the last period (2003-2013), but there was an increase in those related with malignancies, cardiovascular, gastrointestinal, and chronic respiratory diseases. In-hospital mortality remained high (6.8% in the first period vs. 6.3% in the second one), with a progressive increase of non-AIDS-defining illness deaths (37.9% vs. 68.3%, P<.001). The admission rate significantly dropped after 1996 (4.9% yearly), but it was less pronounced in HCV co-infected patients (1.7% yearly).
CONCLUSIONS: Hospital admissions due to infectious and psychiatric disorders have decreased, with a significant increase in non-AIDS-defining malignancies, cardiovascular, and chronic respiratory diseases. In-hospital mortality is currently still high, but mainly because of non-AIDS-defining illnesses. HCV co-infection increased the hospital stay and re-admissions during the study period.
Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Coinfección VIH/VHC; HCV co-infection; HIV/AIDS; Hospital admission; Hospitalización; Re-admission; Reingreso; VIH/sida

Mesh:

Year:  2016        PMID: 27609631     DOI: 10.1016/j.eimc.2016.07.012

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  4 in total

1.  Examining Mortality to Identify Opportunities for Improved Care Among Adults with HIV in a Single Academic Medical Center.

Authors:  Adam M Ressler; Mona Abdo; Samantha MaWhinney; Steven C Johnson; Kristine M Erlandson
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-23       Impact factor: 2.205

2.  Profile of presentation of HIV-positive patients to an emergency department in Johannesburg, South Africa.

Authors:  Abdullah E Laher; Willem D F Venter; Guy A Richards; Fathima Paruk
Journal:  South Afr J HIV Med       Date:  2021-01-29       Impact factor: 2.744

3.  Statistical models for analyzing count data: predictors of length of stay among HIV patients in Portugal using a multilevel model.

Authors:  Ahmed Nabil Shaaban; Bárbara Peleteiro; Maria Rosario O Martins
Journal:  BMC Health Serv Res       Date:  2021-04-21       Impact factor: 2.655

4.  Causes of hospitalisation among a cohort of people with HIV from a London centre followed from 2011 to 2018.

Authors:  Sophia M Rein; Fiona C Lampe; Clinton Chaloner; Adam Stafford; Alison J Rodger; Margaret A Johnson; Jeffrey McDonnell; Fiona Burns; Sara Madge; Alec Miners; Lorraine Sherr; Simon Collins; Andrew Speakman; Andrew N Phillips; Colette J Smith
Journal:  BMC Infect Dis       Date:  2021-04-29       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.